Sana Biotechnology, Inc. (NASDAQ:SANA - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the eight research firms that are presently covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell rating and seven have given a buy rating to the company. The average twelve-month price target among brokers that have covered the stock in the last year is $7.50.
Several equities research analysts have recently weighed in on SANA shares. Morgan Stanley started coverage on shares of Sana Biotechnology in a research report on Thursday, July 3rd. They set an "overweight" rating and a $12.00 price objective for the company. Weiss Ratings reiterated a "sell (e+)" rating on shares of Sana Biotechnology in a research report on Wednesday, October 8th. Finally, Wedbush started coverage on shares of Sana Biotechnology in a research report on Wednesday, September 24th. They set an "outperform" rating and a $5.00 price objective for the company.
View Our Latest Analysis on SANA
Sana Biotechnology Price Performance
SANA stock opened at $5.59 on Friday. The company has a 50 day simple moving average of $3.79 and a 200 day simple moving average of $3.12. The stock has a market cap of $1.33 billion, a price-to-earnings ratio of -5.27 and a beta of 1.91. Sana Biotechnology has a 1 year low of $1.26 and a 1 year high of $7.30.
Sana Biotechnology (NASDAQ:SANA - Get Free Report) last posted its quarterly earnings data on Monday, August 11th. The company reported ($0.16) EPS for the quarter, beating analysts' consensus estimates of ($0.20) by $0.04. On average, equities research analysts anticipate that Sana Biotechnology will post -1.16 EPS for the current fiscal year.
Institutional Investors Weigh In On Sana Biotechnology
A number of large investors have recently bought and sold shares of SANA. Wealth Enhancement Advisory Services LLC acquired a new stake in Sana Biotechnology in the first quarter worth $51,000. Bank of New York Mellon Corp grew its holdings in Sana Biotechnology by 2.1% in the first quarter. Bank of New York Mellon Corp now owns 344,058 shares of the company's stock worth $578,000 after purchasing an additional 7,230 shares during the period. Cerity Partners LLC grew its holdings in Sana Biotechnology by 200.3% in the first quarter. Cerity Partners LLC now owns 46,181 shares of the company's stock worth $78,000 after purchasing an additional 30,801 shares during the period. CWM LLC grew its holdings in Sana Biotechnology by 290.7% in the first quarter. CWM LLC now owns 38,431 shares of the company's stock worth $65,000 after purchasing an additional 28,595 shares during the period. Finally, Summit X LLC acquired a new stake in Sana Biotechnology in the first quarter worth $60,000. 88.23% of the stock is currently owned by institutional investors and hedge funds.
About Sana Biotechnology
(
Get Free Report)
Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Sana Biotechnology, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sana Biotechnology wasn't on the list.
While Sana Biotechnology currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
We are about to experience the greatest A.I. boom in stock market history...
Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.
That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.
- The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
- The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
- Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.
Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.
And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...
Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
